In conclusion, the reduction in α-SMA expression, ECM deposition, and IL-6 levels in CPI-0610-treated lungs demonstrates a convincing ability to reverse pulmonary fibrosis associated with cutaneous lewisite exposure, highlighting the therapeutic potential of BET inhibition in chemical-induced lung injury. Here, ACTA1 is linked to pulmonary fibrosis.